News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,228 Results
Type
Article (14180)
Company Profile (282)
Press Release (251766)
Section
Business (79496)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50433)
Employer Resources (31)
FDA (5711)
Job Trends (5129)
News (144369)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (60)
Alzheimer's disease (822)
Antibody-drug conjugate (ADC) (84)
Approvals (5723)
Artificial intelligence (106)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4561)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (137)
Cancer (1261)
Cardiovascular disease (100)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (303)
Cervical cancer (6)
Clinical research (40820)
Collaboration (492)
Compensation (216)
Complete response letters (13)
COVID-19 (1033)
CRISPR (36)
C-suite (137)
Cystic fibrosis (76)
Data (1301)
Denatured (11)
Depression (28)
Diabetes (122)
Diagnostics (1290)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (76)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (77)
Earnings (29567)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48059)
Executive appointments (396)
FDA (6316)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (459)
Gene editing (87)
Generative AI (9)
Gene therapy (225)
GLP-1 (351)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6585)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (78)
Indications (18)
Infectious disease (1092)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (17)
Intellectual property (55)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (199)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (178)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (114)
MASH (46)
Medical device (2587)
Medtech (2588)
Mergers & acquisitions (6248)
Metabolic disorders (357)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (55)
Neuropsychiatric disorders (23)
Neuroscience (1182)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1505)
Now hiring (21)
Obesity (183)
Opinion (100)
Ovarian cancer (58)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (102)
Partnered (6)
Patents (106)
Patient recruitment (64)
Peanut (35)
People (25477)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14414)
Phase II (18991)
Phase III (12005)
Pipeline (640)
Podcasts (45)
Policy (34)
Postmarket research (852)
Preclinical (6047)
Press Release (30)
Prostate cancer (51)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (268)
Real estate (1414)
Recruiting (12)
Regulatory (8537)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (90)
Series B (58)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1336)
Special edition (11)
Spinal muscular atrophy (116)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11845)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (104)
Women's health (15)
Worklife (2)
Date
Today (102)
Last 7 days (365)
Last 30 days (1722)
Last 365 days (20101)
2025 (4385)
2024 (20553)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16225)
2018 (11739)
2017 (13745)
2016 (11841)
2015 (14354)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7618)
2010 (7430)
Location
Africa (149)
Alabama (38)
Alaska (2)
Arizona (51)
Arkansas (5)
Asia (17193)
Australia (2915)
California (3436)
Canada (1037)
China (312)
Colorado (130)
Connecticut (141)
Delaware (86)
Europe (36992)
Florida (400)
Georgia (105)
Idaho (16)
Illinois (208)
India (7)
Indiana (85)
Iowa (1)
Japan (66)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (439)
Massachusetts (2716)
Michigan (69)
Minnesota (133)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (861)
New Mexico (12)
New York (943)
North Carolina (513)
North Dakota (4)
Northern California (1505)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (654)
Puerto Rico (3)
Rhode Island (14)
South America (209)
South Carolina (4)
Southern California (1336)
Tennessee (25)
Texas (387)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (315)
Wisconsin (13)
266,228 Results for "acorda therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Acorda Therapeutics Announces Delisting from Nasdaq - April 15, 2024
Acorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market.
April 15, 2024
·
5 min read
Deals
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
April 1, 2024
·
8 min read
Policy
Acorda Therapeutics Announces Nasdaq Delisting Notification
Acorda Therapeutics, Inc. announced that Nasdaq Stock Market notified the Company that it will suspend trading in and delist the Company’s common stock, effective with the opening of business on April 12, 2024.
April 3, 2024
·
6 min read
Deals
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz
Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial difficulty. Merz Therapeutics will acquire two commercial medicines from Acorda for $185 million.
April 3, 2024
·
2 min read
·
Tristan Manalac
Deals
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA ® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025.
January 11, 2024
·
6 min read
Business
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023.
November 13, 2023
·
12 min read
Business
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
Acorda Therapeutics, Inc. announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET.
April 1, 2024
·
4 min read
Business
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Acorda Therapeutics, Inc. announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET.
March 25, 2024
·
5 min read
Business
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023.
August 8, 2023
·
14 min read
Pharm Country
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas).
November 6, 2023
·
5 min read
1 of 26,623
Next
